• 1
    Abu-Shakra M, Urowitz M, Gladman D, Gough J. Mortality studies in systemic lupus erythematosus: results from a single center. I. Causes of death. J Rheumatol 1995; 22: 125964.
  • 2
    Shlomchik MC, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001; 1: 14753.
  • 3
    Chan OT, Madaio MP, Shlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 1999; 169: 10721.
  • 4
    Sobel E, Katagiri T, Katagiri K, Morris S, Cohen P, Eisenberg R. An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity. J Exp Med 1991; 173: 14419.
  • 5
    Reininger L, Winkler T, Kalberer C, Jourdan M, Melchers F, Rolink A. Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus. J Exp Med 1996; 184: 85361.
  • 6
    Mohan C, Alas E, Morel L, Yang P, Wakeland EK. Genetic dissection of SLE pathogenesis: Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J Clin Invest 1998; 101: 136272.
  • 7
    Sobel E, Mohan C, Morel L, Schiffenbauer J, Wakeland E. Genetic dissection of SLE pathogenesis: adoptive transfer of Sle1 mediates the loss of tolerance by bone marrow-derived B cells. J Immunol 1999; 162: 241521.
  • 8
    Chan O, Shlomchik MJ. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol 1998; 160: 519.
  • 9
    Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189: 163948.
  • 10
    Kumagai S, Sredni B, House S, Steinberg A, Green I. Defective regulation of B lymphocyte colony formation in patients with systemic lupus erythematosus. J Immunol 1982; 228: 25862.
  • 11
    Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001; 167: 23619.
  • 12
    Khan I, Tsokos G, Kammer G. Abnormal B cell signal transduction in systemic lupus erythematosus. Curr Dir Autoimmun 2003; 6: 89104.
  • 13
    Dar O, Salaman M, Seifert M, Isenberg D. B lymphocyte activation in systemic lupus erythematosus: spontaneous production of IgG antibodies to DNA and environmental antigens in cultures of blood mononuclear cells. Clin Exp Immunol 1988; 73: 4305.
  • 14
    Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165: 59709.
  • 15
    Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15: 4504.
  • 16
    Press O, Howell-Clark J, Anderson S, Bernstein I. Retention of B cell specific monoclonal antibodies by human lymphoma cells. Blood 1994; 83: 13907.
  • 17
    Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JF, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 43545.
  • 18
    Looney RJ, Anolik JH, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004; 16: 1805.
  • 19
    Ward M, Marx A, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000; 27: 66470.
  • 20
    Anolik JH, Campbell D, Felgar R, Young F, Sanz I, Rosenblatt J, et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of SLE. Arthritis Rheum 2003; 48: 4559.
  • 21
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 22
    Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 24150.
  • 23
    Garred P, Voss A, Madsen H, Junker P. Association of mannose-binding lectin gene variation with disease severity and infections in a population based cohort of systemic lupus erythematosus patients. Genes Immun 2001; 2: 44250.
  • 24
    Mamula MJ, Fatenejad S, Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J Immunol 1994; 152: 145361.
  • 25
    Linton PJ, Harbertson J, Bradley LM. A critical role for B cells in the development of memory CD4 cells. J Immunol 2000; 165: 555865.
  • 26
    Skok J, Poudrier J, Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J Immunol 1999; 163: 428491.
  • 27
    Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000; 1: 47582.
  • 28
    Moulin V, Andris F, Thielemans K, Maliszewski C, Urbain J, Moser M. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell deficient mice results in T helper cell type 1 deviation. J Exp Med 2000; 192: 47582.
  • 29
    Bave U, Magnusson M, Eloranta M, Perers A, Alm G, Ronnblom L. FcγRIIa is expressed on natural IFN-α producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J Immunol 2003; 171: 3296302.
  • 30
    Magnusson V, Johanneson B, Lima G, Odeberg J, Alarcon-Segovia D, Alarcon-Riquelme M, et al. Both risk alleles for FcγRIIA and FcγRIIIA are susceptibility factors for SLE: a unifying hypothesis. Genes Immun 2004; 5: 1307.
  • 31
    Sibbitt WJ, Mathews P, Bankhurst A. Natural killer cell in systemic lupus erythematosus: defects in effector lytic activity and response to interferon and interferon inducers. J Clin Invest 1983; 71: 12309.
  • 32
    Wofsy D, Seaman W. Reversal of advance murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol 1987; 138: 324753.
  • 33
    Silverman G, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003; 48: 148492.
  • 34
    Anolik J, Barnard J, Cappione A III, Pugh-Bernard A, Young F, Looney J, et al. Effects of rituximab on B cells in human SLE [abstract]. Arthritis Rheum 2003; 48: S262.
  • 35
    McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 282533.
  • 36
    Maini R St., Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, and the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 19329.
  • 37
    D'Arch C, Mannik M. Serum sickness secondary to treatment with the murine human chimeric antibody IDEC-C2B8. Arthritis Rheum 2001; 44: 17178.
  • 38
    Herishanu Y. Rituximab induced serum sickness. Am J Hematol 2002; 70: 329.
  • 39
    Maeda T, Yamada Y, Tawara M, Yamasaki R, Yakata Y, Tsutsumi C, et al. Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8 rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. Int J Hematol 2001; 74: 705.
  • 40
    Leandro M, Edwards J, Cambridge G, Ehrenstein M, Isenberg D. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 26737.
  • 41
    Zhu L, Cupps T, Whalen G, Fauci A. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest 1987; 79: 108290.
  • 42
    O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199: 918.
  • 43
    Avery D, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thein M, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003; 112: 28697.
  • 44
    Schiemann B, Gommerman JL, Vora K, Cachero TG, Shugla-Motskaya S, Dobles M, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293: 21114.
  • 45
    Rahman Z, Rao S, Kalled S, Manser T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003; 198: 115769.
  • 46
    Albert DA, Khan SR, Stansberry J, Tsai D, Eisenberg RA. A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus [abstract]. Arthritis Rheum 2003; 48: 3659.